JP2024532736A5 - - Google Patents

Info

Publication number
JP2024532736A5
JP2024532736A5 JP2024507886A JP2024507886A JP2024532736A5 JP 2024532736 A5 JP2024532736 A5 JP 2024532736A5 JP 2024507886 A JP2024507886 A JP 2024507886A JP 2024507886 A JP2024507886 A JP 2024507886A JP 2024532736 A5 JP2024532736 A5 JP 2024532736A5
Authority
JP
Japan
Application number
JP2024507886A
Other languages
Japanese (ja)
Other versions
JPWO2023018870A5 (https=
JP2024532736A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/040056 external-priority patent/WO2023018870A1/en
Publication of JP2024532736A publication Critical patent/JP2024532736A/ja
Publication of JPWO2023018870A5 publication Critical patent/JPWO2023018870A5/ja
Publication of JP2024532736A5 publication Critical patent/JP2024532736A5/ja
Pending legal-status Critical Current

Links

JP2024507886A 2021-08-12 2022-08-11 抗体処方物 Pending JP2024532736A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163232299P 2021-08-12 2021-08-12
US63/232,299 2021-08-12
US202263316604P 2022-03-04 2022-03-04
US63/316,604 2022-03-04
PCT/US2022/040056 WO2023018870A1 (en) 2021-08-12 2022-08-11 Antibody formulations

Publications (3)

Publication Number Publication Date
JP2024532736A JP2024532736A (ja) 2024-09-10
JPWO2023018870A5 JPWO2023018870A5 (https=) 2025-08-13
JP2024532736A5 true JP2024532736A5 (https=) 2025-08-13

Family

ID=83151728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024507886A Pending JP2024532736A (ja) 2021-08-12 2022-08-11 抗体処方物

Country Status (16)

Country Link
US (1) US20240343795A1 (https=)
EP (1) EP4384217A1 (https=)
JP (1) JP2024532736A (https=)
KR (1) KR20240046881A (https=)
AU (1) AU2022325870A1 (https=)
CA (1) CA3228269A1 (https=)
CL (1) CL2024000401A1 (https=)
CO (1) CO2024001383A2 (https=)
CR (1) CR20240130A (https=)
IL (1) IL310275A (https=)
JO (1) JOP20240024A1 (https=)
MX (1) MX2024001934A (https=)
PE (1) PE20240650A1 (https=)
TW (1) TW202319398A (https=)
UY (1) UY39896A (https=)
WO (1) WO2023018870A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026062214A1 (en) * 2024-09-19 2026-03-26 Sanofi Formulations comprising lunsekimig

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP2963057A1 (en) 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
WO2017217985A1 (en) 2016-06-15 2017-12-21 Amgen Inc. Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease
WO2018119142A1 (en) * 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
MA48464A (fr) * 2017-04-28 2020-03-04 Amgen Inc Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques
EA201992570A1 (ru) 2017-04-28 2020-03-20 Эмджен Инк. Составы на основе человеческих антител к rankl, а также способы их применения
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗pd-1抗體及治療方法
WO2021079337A1 (en) * 2019-10-23 2021-04-29 Cadila Healthcare Limited Pharmaceutical formulation of anti-her2 antibody and preparation thereof

Similar Documents

Publication Publication Date Title
JP2024532736A5 (https=)
CL2025003731S1 (es) Muralla para maniobras vehiculares
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BY13170U (https=)
BY13166U (https=)
CN307046470S (https=)
CN307046070S (https=)
CN307046032S (https=)
CN307045627S (https=)
CN307045571S (https=)
CN307045178S (https=)
CN307045161S (https=)
CN307044397S (https=)
CN307044191S (https=)
BY23977C1 (https=)
BY23966C1 (https=)
BY23965C1 (https=)
BY13176U (https=)
BY13174U (https=)
BY13172U (https=)
CN307048622S (https=)